Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 50.

Cusini, A; Vernazza, P L; Yerly, S; Decosterd, L A; Ledergerber, B; Fux, C A; Rohrbach, J; Widmer, N; Hirschel, B; Gaudenz, R; Cavassini, M; Klimkait, Th; Zenger, F; Gutmann, C; Opravil, M; Günthard, H F (2013). Higher CNS Penetration-Effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. Journal of Acquired Immune Deficiency Syndromes, 62(1):28-35.

Young, J; Scherrer, A; Günthard, H; Opravil, M; Yerly, S; Böni, J; Rickenbach, M; Fux, C; Cavassini, M; Bernasconi, E; Vernazza, P; Hirschel, B; Battegay, M; Bucher, H (2011). Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. HIV Medicine, 12(5):299-307.

Soriano, V; Arastéh, K; Migrone, H; Lutz, T; Opravil, M; Andrade-Villanueva, J; Antunes, F; Di Perri, G; Podzamczer, D; Taylor, S; Domingo, P; Gellermann, H; de Rossi, L (2011). Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN trial. Antiviral Therapy, 16(3):339-348.

Opravil, M; Klimkait, T; Louvel, S; Wolf, E; Battegay, M; Fux, C A; Bernasconi, E; Vogel, M; Speck, R; Weber, R (2010). Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(1):51-58.

Scherrer, A U; von Wyl, V; Fux, C A; Opravil, M; Bucher, H C; Fayet, A; Decosterd, L A; Hirschel, B; Khanlari, B; Yerly, S; Klimkait, T; Furrer, H; Ledergerber, B; Günthard, H F (2010). Implementation of Raltegravir in routine clinical practice: Selection criteria for choosing this drug, virologic response rates, and characteristics of failures. JAIDS Journal of Acquired Immune Deficiency Syndromes, 53(4):464-471.

Osih, R B; Taffé, P; Rickenbach, M; Gayet-Ageron, A; Elzi, L; Fux, C; Opravil, M; Bernasconi, E; Schmid, P; Günthard, H F; Cavassini, M (2010). Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study. AIDS Research and Human Retroviruses, 26(11):1239-1246.

Elbasha, E E; Szucs, T; Chaudhary, M A; Kumar, R N; Roediger, A; Cook, J R; Opravil, M (2009). Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clinical Trials, 10(4):233-253.

Ballif, M; Ledergerber, B; Battegay, M; Cavassini, M; Bernasconi, E; Schmid, P; Hirschel, B; Furrer, H; Rickenbach, M; Opravil, M; Weber, R (2009). Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. PLoS ONE, 4(12):e8275.

Pozniak, A; Opravil, M; Beatty, G; Hill, A; de Béthune, M P; Lefebvre, E (2008). Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2. AIDS Research and Human Retroviruses, 24(10):1275-1280.

Opravil, M; Sasadeusz, J; Cooper, D A; Rockstroh, J K; Clumeck, N; Clotet, B; Montaner, J; Torriani, F J; Depamphilis, J; Dieterich, D T (2008). Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. JAIDS Journal of Acquired Immune Deficiency Syndromes, 47(1):36-49.

Khanna, N; Opravil, M; Furrer, H; Cavassini, M; Vernazza, P; Bernasconi, E; Weber, R; Hirschel, B; Battegay, M; Kaufmann, G R (2008). CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clinical Infectious Diseases, 47(8):1093-1101.

Nguyen, A; Calmy, A; Schiffer, V; Bernasconi, E; Battegay, M; Opravil, M; Evison, J M; Tarr, P E; Schmid, P; Perneger, T; Hirschel, B; Swiss HIV Cohort Study (2008). Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Medicine, 9(3):142-150.

Opravil, M; Sereni, D (2008). Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS, 22(Suppl 3):35-40.

Landovitz, R J; Angel, J B; Hoffmann, C; Horst, H; Opravil, M; Long, J; Greaves, W; Fätkenheuer, G (2008). Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. Journal of Infectious Diseases, 198(8):1113-1122.

Rauch, A; Nolan, D; Thurnheer, C; Fux, C; Cavassini, M; Chave, J P; Opravil, M; Phillips, E; Mallal, S; Furrer, H; Swiss HIV Cohort Study (2008). Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antiviral Therapy, 13(8):1019-1028.

Fux, C; Rauch, A; Simcock, M; Bucher, H; Hirschel, B; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Elzi, L; Furrer, H; Swiss HIV Cohort Study (2008). Tenofovir Use Is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 13:1077-1082.

Eich, D; Neuhaus, C; Gamma, A; Angst, J; Rossler, W; Ajdacic-Gross, V; Opravil, M (2007). Is depression a risk factor for heart complaints? Longitudinal aspects in the Zurich study. European Archives of Psychiatry and Clinical Neuroscience, 257(7):396-401.

Schüpbach, J; Tomasik, Z; Knuchel, M C; Opravil, M; Günthard, H F; Nadal, D; Böni, J (2006). Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART. Journal of Medical Virology, 78(8):1003-1010.

Huttner, B; Opravil, M (2006). Die infektiöse Spondylitis. Zeitschrift für Rheumatologie, 65(1):7-11.

Kaufmann, G R; Furrer, H; Ledergerber, B; Perrin, L; Opravil, M; Vernazza, P; Cavassini, M; Bernasconi, E; Rickenbach, M; Hirschel, B; Battegay, M (2005). Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clinical Infectious Diseases, 41(3):361-372.

Zinkernagel, A S; von Overbeck, J; Opravil, M; Jenni, R; Speich, R; Mueller, N J (2005). Long-term survival and interruption of HAART in HIV-related pulmonary hypertension. European Journal of Clinical Microbiology & Infectious Diseases, 24(2):153-155.

Opravil, M; Zuber, J-P; Speich, R (2004). Reply to Torre and Pugliese. Clinical Infectious Diseases, 39(10):1550.

Zingg, W; Renner-Schneiter, E C; Pauli-Magnus, C; Renner, E L; van Overbeck, J; Schläpfer, E; Weber, M; Weber, R; Opravil, M; Gottstein, B; Speck, R F (2004). Alveolar Echinococcosis of the Liver in an Adult with Human Immunodeficiency Virus Type-1 Infection. Infection, 32(5):299-302.

Oxenius, A; Price, D A; Hersberger, M; Schlaepfer, E; Weber, R; Weber, M; Kundig, T M; Böni, J; Joller, H; Phillips, R E; Flepp, M; Opravil, M; Speck, R F (2004). HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load. Journal of Infectious Diseases, 189(7):1199-1208.

Haupts, S; Ledergerber, B; Böni, J; Schüpbach, J; Kronenberg, A; Opravil, M; Flepp, M; Speck, R F; Grube, C; Rentsch, K; Weber, R; Günthard, H F (2003). Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral Therapy, 8(5):443-454.

Schüpbach, J; Böni, J; Bisset, L R; Tomasik, Z; Fischer, M; Günthard, H F; Ledergerber, B; Opravil, M (2003). HIV-1 p24 antigen is a significant inverse correlate of CD4 T-cell change in patients with suppressed viremia under long-term antiretroviral therapy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 33(3):292-299.

Boubaker, K; Flepp, M; Sudre, P; Furrer, H; Haensel, A; Hirschel, B; Boggian, K; Chave, J‐P; Bernasconi, E; Egger, M; Opravil, M; Rickenbach, M; Francioli, P; Telenti, A (2001). Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 33(11):1931-1937.

Schüpbach, J; Böni, J; Flepp, M; Tomasik, Z; Joller, H; Opravil, M (2001). Antiretroviral treatment monitoring with an improved HIV-1 p24 antigen test: an inexpensive alternative to tests for viral RNA. Journal of Medical Virology, 65(2):225-232.

Eich-Höchli, Dominique; Niklowitz, M; Eich, P; Zellweger, Ueli; Opravil, M (2001). Gibt es Prädiktoren für sexuelles Risikoverhalten bei HIV-Infizierten? Der Nervenarzt, 72(3):216-223.

Speich, R; Jenni, R; Opravil, M; Jaccard, R (2001). Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Medical Weekly, 131(45-46):663-665.

Schüpbach, J; Tomasik, Z; Nadal, D; Ledergerber, B; Flepp, M; Opravil, M; Böni, J (2000). Use of HIV-1 p24 as a sensitive, precise and inexpensive marker for infection, disease progression and treatment failure. International Journal of Antimicrobial Agents, 16(4):441-445.

Fischer, M; Günthard, H F; Opravil, M; Joos, B; Huber, W; Bisset, L R; Ott, P; Böni, J; Weber, R; Cone, R W (2000). Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Research and Human Retroviruses, 16(12):1135-1140.

Opravil, M; Cone, R W; Fischer, M; Vernazza, P L; Bassetti, S; Lorenzi, P; Bisset, L R; Ott, P; Huber, W; Knuchel, M C; Roos, Malgorzata; Lüthy, R; Weber, R (2000). Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV cohort study. Journal of Acquired Immune Deficiency Syndromes, 23(1):17-25.

Yerly, S; Rutschmann, O T; Opravil, M; Marchal, F; Hirschel, B; Perrin, L (1999). Cell‐Associated HIV‐1 RNA in Blood as Indicator of Virus Load in Lymph Nodes. Journal of Infectious Diseases, 180(3):850-853.

Kaufmann, P; Opravil, M; Hauser, M; Gaspert, A; Laube, I; Jenni, R; Speich, R (1999). Die Pseudomonas-Pneumonie – eine wichtige Differentialdiagnose pulmonaler Infiltrate bei Aids. Swiss Medical Weekly, 129(4):120-130.

Böni, J; Opravil, M; Tomasik, Z; Rothen, M; Bisset, L; Grob, P J; Lüthy, R; Schüpbach, J (1997). Simple monitoring of antiretroviral therapy with a signal-amplification-boosted HIV-1 p24 antigen assay with heat-denatured plasma. AIDS, 11(6):F47-F52.

Opravil, M; Pechère, M; Speich, R; Joller-Jemelka, H I; Jenni, R; Russi, E W; Hirschel, B; Lüthy, R (1997). HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. American Journal of Respiratory and Critical Care Medicine, 155(3):990-995.

Opravil, M; Hirschel, B; Lazzarin, A; Heald, A; Pechere, M; Ruttimann, S; Iten, A; von Overbeck, J; Oertle, D; Praz, G; Vuitton, D A; Mainini, F; Luthy, R (1995). Once-Weekly Administration of Dapsone/Pyrimethamine vs. Aerosolized Pentamidine as Combined Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic Encephalitis in Human Immunodeficiency Virus-Infected Patients. Clinical Infectious Diseases, 20(3):531-541.

Opravil, M; Pechere, M; Lazzarin, A; Heald, A; Ruttimann, S; Iten, A; Furrer, H; Oertle, D; Praz, G; Vuitton, D A; Hirschel, B; Luthy, R (1995). Dapsone/Pyrimethamine May Prevent Mycobacterial Disease in Immunosuppressed Patients Infected with the Human Immunodeficiency Virus. Clinical Infectious Diseases, 20(2):244-249.

Gruner, E; Opravil, M; Altwegg, M; von Graevenitz, A (1994). Nontoxigenic Corynebacterium diphtheriae Isolated from Intravenous Drug Users. Clinical Infectious Diseases, 18(1):94-96.

Zaugg, M; Salfinger, M; Opravil, M; Luthy, R (1993). Extrapulmonary and Disseminated Infections Due to Mycobacterium malmoense: Case Report and Review. Clinical Infectious Diseases, 16(4):540-549.

Teuscher, A U; Opravil, M; Theiler, R; Speich, R; Kuster, H; Siegenthaler, W; Russi, E W; Lüthy, R (1993). Predictive value of bronchoalveolar lavage in excluding a diagnosis of Pneumocystis carinii pneumonia during prophylaxis with aerosolized pentamidine. Clinical Infectious Diseases, 16(4):519-522.

Speich, R; Opravil, M; Weber, R; Hess, T; Luethy, R; Russi, E W (1992). Prospective evaluation of a prognostic score for Pneumocystis carinii pneumonia in HIV-infected patients. Chest, 102(4):1045-1048.

Teuscher, A U; Opravil, M; Speich, R; Kuster, H; Siegenthaler, W; Russi, E W; Lüthy, R (1992). Diagnose und Verlauf nach Ausschluß einer Pneumocystis-carinii-Pneumonie bei HIV-Infizierten. Deutsche Medizinische Wochenschrift, 117(27):1052-1056.

Reiser, P; Opravil, M; Pfaltz, M; Speich, R; Schneider, J (1992). Primäre pulmonale Hypertonie und mesangioproliferative Glomerulonephritis bei HIV-Infektion. Deutsche Medizinische Wochenschrift, 117(21):815-818.

Massenkeil, G; Opravil, M; Salfinger, M; von Graevenitz, A; Luthy, R (1992). Disseminated Coinfection with Mycobacterium avium Complex and Mycobacterium kansasii in a Patient with AIDS and Liver Abscess. Clinical Infectious Diseases, 14(2):618-619.

Speich, R; Jenni, R; Opravil, M; Pfab, M; Russi, E W (1991). Primary pulmonary hypertension in HIV infection. Chest, 100(5):1268-1271.

Weber, R; Opravil, M; Bloch, K; Speich, R; Linnenberg, H S; Kuster, H; Kägi, M; Jacquier, P; Eckert, J; Russi, E W (1990). Pneumocystis-carinii-Pneumonie bei HIV-Infektion: bessere Prognose durch frühe Diagnose. Deutsche Medizinische Wochenschrift, 115(43):1619-1623.

Opravil, M; Weber, R; Ledergerber, B; Speich, R; Siegenthaler, W; Lüthy, R (1990). Compliance and laboratory data predict relapse rate of Pneumocystis carinii pneumonia during prophylaxis with aerosol pentamidine. Klinische Wochenschrift, 68(8):397-402.

Speich, R; Weber, R; Kronauer, C M; Opravil, M; Lüthy, R; Russi, E W (1990). Prognostic score for Pneumocystis carinii pneumonia. Respiration, 57(4):259-263.

This list was generated on Wed Jun 19 09:47:24 2019 CEST.